Race, insulin resistance and hepatic steatosis in chronic hepatitis C Potential conflict of interest: Dr. Zacks is on the speakers' bureau of Roche. He also received grants from Salix Pharmaceuticals.
dc.contributor.author | Conjeevaram, Hari S. | en_US |
dc.contributor.author | Kleiner, David E. | en_US |
dc.contributor.author | Everhart, Jay E. | en_US |
dc.contributor.author | Hoofnagle, Jay H. | en_US |
dc.contributor.author | Zacks, Steven | en_US |
dc.contributor.author | Afdhal, Nezam H. | en_US |
dc.contributor.author | Wahed, Abdus S. | en_US |
dc.date.accessioned | 2007-09-20T17:55:22Z | |
dc.date.available | 2008-04-03T18:45:01Z | en_US |
dc.date.issued | 2007-01 | en_US |
dc.identifier.citation | Conjeevaram, Hari S.; Kleiner, David E.; Everhart, Jay E.; Hoofnagle, Jay H.; Zacks, Steven; Afdhal, Nezam H.; Wahed, Abdus S. (2007). "Race, insulin resistance and hepatic steatosis in chronic hepatitis C Potential conflict of interest: Dr. Zacks is on the speakers' bureau of Roche. He also received grants from Salix Pharmaceuticals. ." Hepatology 45(1): 80-87. <http://hdl.handle.net/2027.42/55881> | en_US |
dc.identifier.issn | 0270-9139 | en_US |
dc.identifier.issn | 1527-3350 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/55881 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17187406&dopt=citation | en_US |
dc.description.abstract | Hepatic steatosis is common in chronic hepatitis C and has been linked to concurrent obesity, insulin resistance, diabetes, disease severity, and poor response to therapy. Racial differences in rates of obesity and diabetes may contribute to racial differences in hepatic steatosis and treatment response. The aim of the present study was to compare hepatic steatosis and its associations between African American (AA) and Caucasian American (CA) patients with chronic hepatitis C, genotype 1, participating in a prospective study of peginterferon and ribavirin therapy. Liver biopsy results were available from 194 AA patients and 205 CA patients. The 2 groups were compared for anthropometric, clinical, and biochemical features and insulin resistance estimated by the homeostasis model assessment index (HOMA-IR). Sixty-one percent of the AA patients and 65% of the CA patients had hepatic steatosis ( P = 0.38). In univariable analysis, steatosis was associated with HOMA-IR, body mass index, waist circumference, serum triglycerides, aminotransferase level, and histological scores for inflammation and fibrosis. After adjusting for these features, AA patients had a lower risk of steatosis than did CA patients (OR 0.54, 95% CI 0.32-0.91, P = 0.02). Insulin resistance but not steatosis was associated with a lower rate of sustained virological response when adjusted for known factors that predict response (relative risk 0.87, 95% CI 0.77-0.99, P = 0.028). Conclusion : After adjusting for the higher prevalence of features associated with hepatic steatosis, AA patients had a lower prevalence of hepatic steatosis than did CA patients with chronic hepatitis C, genotype 1. Insulin resistance but not steatosis was independently associated with lower sustained virological response. (H EPATOLOGY 2006;45:80–87.) | en_US |
dc.format.extent | 150621 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Hepatology | en_US |
dc.title | Race, insulin resistance and hepatic steatosis in chronic hepatitis C Potential conflict of interest: Dr. Zacks is on the speakers' bureau of Roche. He also received grants from Salix Pharmaceuticals. | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor, MI ; fax: (734) 936-7392 ; Division of Gastroenterology, University of Michigan, 3912 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0362 | en_US |
dc.contributor.affiliationother | National Cancer Institute, National Institutes of Health, Bethesda, MD | en_US |
dc.contributor.affiliationother | National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD | en_US |
dc.contributor.affiliationother | National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD | en_US |
dc.contributor.affiliationother | University of North Carolina at Chapel Hill, Chapel Hill, NC | en_US |
dc.contributor.affiliationother | Beth Israel Deaconess Medical Center, Boston, MA | en_US |
dc.contributor.affiliationother | University of Pittsburgh, Pittsburgh, PA | en_US |
dc.identifier.pmid | 17187406 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/55881/1/21455_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/hep.21455 | en_US |
dc.identifier.source | Hepatology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.